Ardelyx(US:ARDX) ZACKSยท2025-07-28 15:06Company Overview - Ardelyx (ARDX) is expected to report a year-over-year decline in earnings despite higher revenues for the quarter ended June 2025, with a consensus outlook indicating a quarterly loss of $0.13 per share, representing an 85.7% decrease from the previous year [1][3] - Revenues are projected to be $84.64 million, reflecting a 15.6% increase compared to the same quarter last year [3] Earnings Expectations - The earnings report is anticipated to be released on August 4, and the stock may experience upward movement if the reported numbers exceed expectations; conversely, a miss could lead to a decline in stock price [2] - The consensus EPS estimate has been revised down by 6.25% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4] Earnings Surprise Prediction - The Most Accurate Estimate for Ardelyx is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.18%, which suggests a bearish outlook from analysts [12] - The company currently holds a Zacks Rank of 4, making it challenging to predict a beat on the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Ardelyx was expected to post a loss of $0.10 per share but actually reported a loss of $0.17, resulting in a surprise of -70.00% [13] - Over the past four quarters, Ardelyx has beaten consensus EPS estimates two times [14] Industry Comparison - In the Zacks Medical - Drugs industry, United Therapeutics (UTHR) is expected to report earnings of $6.8 per share for the same quarter, indicating a year-over-year increase of 16.2% [18] - United Therapeutics' revenue is projected to be $795.75 million, up 11.3% from the previous year, with a revised consensus EPS estimate down by 2.4% over the last 30 days but an Earnings ESP of +7.09% [19][20]